NCT03096340: Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer

NCT03096340
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known unstable brain metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT03096340

Comments are closed.

Up ↑